| Literature DB >> 35227212 |
Tomohiro Taniguchi1,2, Sanefumi Tsuha3,4, Soichi Shiiki3, Masashi Narita3.
Abstract
BACKGROUND: Febrile urinary tract infections (fUTIs), which include pyelonephritis, prostatitis, and urosepsis, are the most common cause of sepsis. However, the treatment has become more complex because of the worldwide increase in antimicrobial resistance (AMR). The objective of this study was to clarify whether point-of-care Gram stain (PCGS) of urine contributed to fUTI diagnosis and treatment in adults.Entities:
Keywords: Antimicrobial resistance; Febrile urinary tract infection; Point-of-care Gram stain; Prostatitis; Pyelonephritis; Urine Gram stain
Mesh:
Substances:
Year: 2022 PMID: 35227212 PMCID: PMC8886832 DOI: 10.1186/s12879-022-07194-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Agreement between bacteria estimation using urine PCGS and urine culture results
| Uncomplicated group (N = 47) | |||
|---|---|---|---|
| Urine culture | |||
| Enterobacteriaceae | Nonpathogenic | ||
| Urine PCGS | |||
| GNR middle or large size | 44 | 0 | 0 |
| GPC in chains | 0 | 0 | 0 |
| Nonpathogenic | 0 | 0 | 2 |
| Negative | 3 | 2 | 0 |
| Kappa (95% CI) = 0.518 (0.318–0.547) | |||
CI confidence interval
GNR Gram-negative rods
GPC Gram-positive cocci
PCGS point-of-care Gram stain
Comparison between uncomplicated and complicated groups
| Uncomplicated group (N = 48) | Complicated group (N = 218) | ||
|---|---|---|---|
| Median age (IQR) | 41 (31–60) | 80 (69–88) | < 0.0001* |
| Female sex | 48 (100%) | 139 (63.8%) | < 0.001* |
| Performance status | |||
| 0–2 | 48 (100%) | 144 (66.0%) | < 0.001* |
| 3–4 (in bed more than 50%) | 0 | 74 (33.9%) | < 0.001* |
| Living place before admission | |||
| Home | 48 (100%) | 156 (71.6%) | < 0.001* |
| Nursing facility or hospital | 0 | 62 (28.4%) | < 0.001* |
| Symptom duration days (IQR) | 2 (1–3) | 1 (0–2) | 0.0065* |
| Bladder inflammatory symptoms | 36 (75.0%) | 73 (33.5%) | < 0.001* |
| Shaking chills | 35 (72.9%) | 85 (39.0%) | < 0.001* |
| Physical examinations | |||
| CVA tenderness | 38 (79.2%) | 46 (21.1%) | < 0.001* |
| Bimanual palpation | 38 (79.2%) | 48 (22.0%) | < 0.001* |
| Prostate tenderness | 0 | 20 (27.8%) | 0.029* |
| Catecholamine support needed | 1 (2.1%) | 7 (3.2%) | 1.000 |
| Urinalysis | |||
| Pyuria | 46 (95.8%) | 215 (99.1%) | 0.15 |
| Bacteriuria | 47 (97.9%) | 212 (97.7%) | 0.70 |
| Urine PCGS | |||
| Pyuria | 48 (100%) | 215 (98.6%) | 0.55 |
| Bacteriuria | 45 (93.8%) | 213 (97.7%) | 0.16 |
| Urine culture results | |||
| Nonpathogenic 1 | |||
| Others 10 | |||
| Nonpathogenic 11 | |||
| Negative 1 | |||
| Blood culture positivity | 8 (16.7%) | 67 (30.7%) | 0.053 |
| Blood culture results | |||
| Others 6 | |||
| Antimicrobial resistance | 1 (2.1%) | 32 (14.7%) | 0.014* |
| Initial antibiotics | |||
| Based on PCGS | 45 (93.8%) | 184 (84.4%) | 0.064 |
| Based on previous cultures | 1 (2.1%) | 31 (14.2%) | 0.010* |
| Empirical treatment | 2 (4.1%) | 3 (1.4%) | 0.22 |
| Death | 0 | 2 (0.9%) | 0.51 |
CVA costovertebral angle
IQR interquartile range
PCGS point-of-care Gram stain
*p < 0.05
Pyuria and bacteriuria detection by PCGS and U/A
| Uncomplicated group (N = 48) | ||||||
|---|---|---|---|---|---|---|
| U/A WBC 1–4 | 5–9 | 10–29 | 30–49 | 50–100/HPF | Total | |
| PCGS WBC | ||||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ± | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 + | 2 | 2 | 8 | 0 | 3 | 15 |
| 2 + | 0 | 0 | 4 | 6 | 13 | 23 |
| 3 + | 0 | 0 | 0 | 2 | 8 | 10 |
| Total | 2 | 2 | 12 | 8 | 24 | |
p < 0.001
HPF high power field
PCGS point-of-care Gram stain
U/A urinalysis
WBC white blood cell
Comparison between bacterial PCGS semi-quantification and urine culture quantification
| Uncomplicated group (N = 47) | |||||
|---|---|---|---|---|---|
| Urine culture | |||||
| 104 | 105 | 106 | 107 CFU/mL | Total | |
| PCGS bacteria | |||||
| 0 | 1 | 1 | 1 | 0 | 3 |
| ± | 2 | 5 | 0 | 1 | 8 |
| 1 + | 1 | 0 | 1 | 6 | 8 |
| 2 + | 0 | 1 | 4 | 17 | 22 |
| 3 + | 0 | 0 | 0 | 6 | 6 |
| Total | 4 | 7 | 6 | 30 | |
p<0.001
CFU, colony-forming units
PCGS, point-of-care Gram stain
Initial antibiotic susceptibility
| Uncomplicated group (N = 48) | Complicated group (N = 218) | ||
|---|---|---|---|
| Narrow spectrum | 46/47 (97.9%) | 142/170 (83.5%) | < 0.001* |
| Ampicillin | 5/5 | ||
| Ampicillin/sulbactam | 1/3 | ||
| Cefazolin | 2/2 | ||
| Cefotiam | 46/47 | 134/160 | |
| Intermediate spectrum | 1/1 (100%) | 29/34 (85.3%) | 1.000 |
| Cefmetazole | 10/12 | ||
| Cefotaxime or ceftriaxone | 1/1 | 11/13 | |
| Ceftazidime | 5/5 | ||
| Aztreonam | 2/3 | ||
| Tobramycin | 1/1 | ||
| Broad spectrum | 0 | 16/17 (94.1%) | |
| Imipenem/cilastatin | 8/8 | ||
| Meropenem | 6/7 | ||
| Vancomycin | 2/2 | ||
| Total | 47/48 (97.9%) | 186/221 (84.2%) | 0.009* |
*p < 0.05
Final antibiotic administered intravenously after urine culture results
| Uncomplicated group (N = 48) | Complicated group (N = 218) | |
|---|---|---|
| Narrow spectrum | 44 (91.7%) | 150 (67.8%) |
| Ampicillin | 34 | 80 |
| Ampicillin/sulbactam | 1 | |
| Cefazolin | 4 | |
| Cefotiam | 10 | 65 |
| Intermediate spectrum | 4 (8.3%) | 54 (24.4%) |
| Cefmetazole | 1 | 17 |
| Cefotaxime or ceftriaxone | 2 | 10 |
| Ceftazidime | 4 | |
| Aztreonam | 1 | 5 |
| Tobramycin | 15 | |
| Ciprofloxacin | 3 | |
| Broad spectrum | 0 | 17 (7.7%) |
| Cefepime | 3 | |
| Imipenem/cilastatin | 7 | |
| Meropenem | 4 | |
| Vancomycin | 3 |